相关实验视频

Updated: Jun 5, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

福福克斯-HAIC结合针对性免疫治疗最初无法切除的肝细胞癌:一个现实世界的研究

Yan-Cen Lu¹, Yu-Chen Yang¹, Di Ma¹

¹Department of General Surgery, Hepatobiliary Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Frontiers in immunology

|December 11, 2024

概括

肝动脉输液化疗 (HAIC) 使用FOLFOX与向免疫疗法相结合,对不可切除的肝癌显示出有前途. 这种治疗在HCC患者中实现了高响应率和显著的手术转换率.

科学领域:

肝胆道癌症肝胆道癌症
医学瘤学医学瘤学
胃肠病学胃肠病学

背景情况:

无法切除的肝细胞癌 (HCC) 仍然是一个挑战.
使用FOLFOX的肝动脉输液化疗 (HAIC) 显示出有效性.
联合向和免疫疗法是肝癌的新一线治疗方法.

研究的目的:

评估FOLFOX-HAIC与向免疫治疗相结合的临床疗效和安全性.
评估这种疗法作为未经治疗,无法切除的HCC.的潜在第一线治疗方案.

主要方法:

从2022年6月到2023年6月接受治疗的51名无法切除的HCC患者的回顾性研究.
与向免疫疗法结合的FOLFOX-HAIC被使用.
评估了瘤反应 (mRECIST,RECIST 1.1),生存结果和不良事件.

主要成果:

客观反应率分别为60.8% (mRECIST) 和45.1% (RECIST 1.1) 的情况.
手术转换率为25.5%. 在手术转换率为25.5%.
中位数无进展生存时间为15.2个月; 一年总生存率为88.2%.
98%的患者经历了不良事件,其中23.5%有3级或4级事件.

结论:

与向免疫疗法相结合的FOLFOX-HAIC对不可切除的HCC有效.
该方案提供了高的手术转换率和可控的副作用.
这种组合代表了一种潜在的新型第一线治疗HCC.

关键词:

这就是FOLFOX-HAICIC.综合疗法综合疗法转换疗法的转换疗法.肝细胞癌是肝细胞癌.免疫疗法免疫疗法有针对性的治疗.不能切除的晚期癌症.

更多相关视频

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Published on: January 9, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.